New therapeutic strategies for echinococcosis: modification on the drug release to increase bioavailability and efficacy.

ELISSONDO MARÍA CELINA

Mar del Plata

Congreso; Reunión Conjunta 2016 SAIC, SAI, SAFE.; 2016

SAIC, SAI, SAFE.

Echinocccosis, also known as hydatid disease or hydatidosis, is a parasitic zoonoses caused by infection with the larval stage of the cestode Echinococcus spp. The World Health Organization has recently included human echinococcosis within the group of neglected tropical diseases, and recommends a veterinary public health strategy as part of an effective control approach.Depending on different factors such as cyst number, size and location, viability status, the involved organ and location, the interaction between the expanding parasite and the adjacent host tissue and bacterial and fungal infection, there are different treatment and management options human echinococcosis.In the last 30 years, an increase in the use of anthelmintic drugs for the medical treatment of echinococcosis was observed. The only two drugs licensed to date are the benzimidazole carbamate derivatives albendazole and mebendazole. Albendazole belongs to Class II of the biopharmaceutical classification system, with high permeability and low aqueous solubility. Approximately a third of the patients treated with benzimidazole drugs have been cured, 30?50% develop some evidence of a therapeutic response while between 20 and 40% of cases do not respond favourably. Therapeutic failures attributed to medical management of echinococcosis with albendazole have been primarily linked to the poor drug absorption rate (